Bone Biologics Corp (Bone Biologics) is a biotechnology company which develops orthobiologic products. It develops NELL-1, a recombinant human protein growth factor, which is essential for normal bone development. It offers bone graft substitutes for spine fusion. Bone Biologics also offers NELL-1/DBX fusion device, which is a single dose vial of Nell-1 recombinant protein freeze dried onto tricalcium phosphate and demineralized bone putty. The company's technology has application in spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicines, among others. It collaborates with manufacturing organizations to develop its products. The company markets its products domestic and internationally. Bone Biologics is headquartered in Burlington, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Bone Biologics Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Bone Biologics Corp Company Overview
- Bone Biologics Corp Company Snapshot
- Bone Biologics Corp Pipeline Products and Ongoing Clinical Trials Overview
- Bone Biologics Corp - Pipeline Analysis Overview
- Bone Biologics Corp - Key Facts
- Bone Biologics Corp - Major Products and Services
- Bone Biologics Corp Pipeline Products by Development Stage
- Bone Biologics Corp Ongoing Clinical Trials by Trial Status
- Bone Biologics Corp Pipeline Products Overview
- NB1 Bone Graft
- NB1 Bone Graft Product Overview
- NB1 Bone Graft Clinical Trial
- NELL-1/DBX Fusion Device - Osteoporosis
- NELL-1/DBX Fusion Device - Osteoporosis Product Overview
- NELL-1/DBX Fusion Device - Trauma
- NELL-1/DBX Fusion Device - Trauma Product Overview
- UCS-1
- UCS-1 Product Overview
- Bone Biologics Corp - Key Competitors
- Bone Biologics Corp - Key Employees
- Bone Biologics Corp - Locations And Subsidiaries
- Head Office
- Recent Developments
- Bone Biologics Corp, Recent Developments
- Mar 01, 2024: Bone Biologics Reports Progress with NB1 Clinical Program
- Apr 12, 2023: Bone Biologics gets approval for NB1 bone graft pilot study in Australia
- Jan 26, 2023: Bone Biologics advances preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
- Mar 07, 2022: Bone Biologics enters into supply agreement with MTF Biologics for demineralized bone matrix
- Jan 07, 2020: Bone Biologics preclinical study shows rhNELL-1 effectively promotes bone formation
- Mar 25, 2019: Bone Biologics receives Human Research Ethics Committee (HREC) approval for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX) in Australia
- Dec 20, 2017: Bone Biologics: New Preclinical Data For Spine Fusion Demonstrates Osteopromotive Properties
- Aug 03, 2017: Bone Biologics Announces Appointment of Bret Hankey to Company’s Board of Director
- Jul 06, 2016: Bone Biologics Names Scott D. Boden, MD Chief Medical Advisor
- Aug 13, 2015: Bone Biologics Appoints New Chief Executive Officer and a Chief Operating Officer
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Bone Biologics Corp Pipeline Products and Ongoing Clinical Trials Overview
- Bone Biologics Corp Pipeline Products by Equipment Type
- Bone Biologics Corp Pipeline Products by Indication
- Bone Biologics Corp Ongoing Clinical Trials by Trial Status
- Bone Biologics Corp, Key Facts
- Bone Biologics Corp, Major Products and Services
- Bone Biologics Corp Number of Pipeline Products by Development Stage
- Bone Biologics Corp Pipeline Products Summary by Development Stage
- Bone Biologics Corp Ongoing Clinical Trials by Trial Status
- Bone Biologics Corp Ongoing Clinical Trials Summary
- NB1 Bone Graft - Product Status
- NB1 Bone Graft - Product Description
- NB1 Bone Graft - A Multi-center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety and Preliminary Effectiveness of NB1 Bone Graft in Subjects with Degenerative Disc Disease Undergoing Transforaminal Lumbar Interbody Fusion
- NELL-1/DBX Fusion Device - Osteoporosis - Product Status
- NELL-1/DBX Fusion Device - Osteoporosis - Product Description
- NELL-1/DBX Fusion Device - Trauma - Product Status
- NELL-1/DBX Fusion Device - Trauma - Product Description
- UCS-1 - Product Status
- UCS-1 - Product Description
- Bone Biologics Corp, Key Employees
- Glossary
- Bone Biologics Corp Pipeline Products by Equipment Type
- Bone Biologics Corp Pipeline Products by Development Stage
- Bone Biologics Corp Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Tissue Regeneration Technologies LLC
- Bellicum Pharmaceuticals Inc
- Globus Medical Inc
- NovaBone Products LLC
- Surgalign Holdings Inc
